| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_UBAP2_0004300 | Exon-Exon | chr9:33935837-33944637 | chr9:33935839-33944639 | 699 nt | 0.4778 |
| hsa_UBAP2_0004400 | Exon-Exon | chr9:33935837-33948585 | chr9:33935839-33948587 | 913 nt | 0.4841 |
| hsa_UBAP2_0004500 | Exon-Exon | chr9:33935837-33963789 | chr9:33935839-33963791 | 1290 nt | 0.4845 |
| hsa_UBAP2_0004600 | Exon-Exon | chr9:33935837-33973235 | chr9:33935839-33973237 | 1449 nt | 0.4859 |
| hsa_UBAP2_0004700 | Exon-Exon | chr9:33935837-33989124 | chr9:33935839-33989126 | 1681 nt | 0.4789 |
| hsa_UBAP2_0004800 | Exon-Exon | chr9:33935837-34017187 | chr9:33935839-34017189 | 2010 nt | 0.4647 |
| hsa_UBAP2_0005400 | Exon-Exon | chr9:33941647-33943587 | chr9:33941649-33943589 | 384 nt | 0.4453 |
| hsa_UBAP2_0005500 | Exon-Exon | chr9:33941647-33944637 | chr9:33941649-33944639 | 659 nt | 0.4765 |
| hsa_UBAP2_0005600 | Exon-Exon | chr9:33941647-33948585 | chr9:33941649-33948587 | 873 nt | 0.4834 |
| hsa_UBAP2_0005700 | Exon-Exon | chr9:33941647-33953472 | chr9:33941649-33953474 | 1063 nt | 0.4920 |
A review of literature indicates that the circUBAP2 is an oncogenic circular RNA upregulated in osteosarcoma patient samples, where its high expression is correlated with lower overall survival and promotes tumor growth while inhibiting apoptosis [Di Agostino et al. DOI:10.3389/fcell.2020.00389]. A study in human patients with heart failure after acute myocardial infarction demonstrated that the expression level of the circUBAP2 was not significantly different between patients with sacubitril/valsartan resistance and non-resistant patients in quantitative real-time PCR validation [Su et al. DOI:10.1016/j.ejphar.2023.175547].